Sanofi-Aventis: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Sanofi-Aventis in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into Sanofi-Aventis's strategic outlook across the next 6 years.* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
Highlights

Strategic insight into the prospects for Sanofi-Aventis over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

* Benchmark Sanofi-Aventis's performance against key rivals in the prescription pharmaceutical sector.* Analyse the positioning of the company as a diversified healthcare player with an enhanced focus on the vaccine, generic and consumer markets.* Assess how the genericization of blockbusters Plavix, Eloxatine, Taxotere, Stilnox/Ambien and Lovenox is expected to significantly impact growth.

[Studien Infos ausblenden]

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Sanofi-Aventis: PharmaVitae forecasts at a glance
Strategic insight
[Missing title]
Diversification will struggle to address near-term impact of generic exposure
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY UPDATE
Latest quarterly sales
Latest quarterly financial analysis
Q3 2010
Q2 2010
Latest comment
Q4 2010
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Latest prescription pharma product news
Q4 2010
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Latest corporate news
Q4 2010
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Future product milestones
COMPANY INTRODUCTION
Key findings
M&A history
Sanofi-Synthélabo: established in 1999
Aventis: result of Hoechst and Rhone-Poulenc merger
Sanofi-Aventis: merged in 2004
Subsequent M&A promotes diversified business model
M&A strategy
a) Dilution of exposure to patent expiry risk across blockbuster portfolio
b) Establish a diversified business model
c) Creation of industry-leading player in the global thrombosis market
d) Expansion of geographic presence
Current corporate structure
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Generics analysis, 2009-15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS
Key findings
Overview
Lantus
Vaccines
aflibercept
Lovenox
Plavix
Aprovel/CoAprovel
Taxotere
Eloxatine
APPENDIX
References
Abbreviations
Exchange rates

[Inhaltsverzeichnis ausblenden]